VectivBio Holding AG
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Luca Santarelli
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Aeschenvorstadt 36 Basel Switzerland 4051
- IPO Date
- Apr 8, 2021
- CIK
- 0001836379
- Website
- vectivbio.com
- Similar Companies
- Business
- VectivBio Holding AG, a clinical-stage biopharmaceutical company, discovers, develops and commercializes innovative medicines for severe rare gastrointestinal conditions, including short bowel syndrome with intestinal failure (SBS-IF) and steroid-refractory gastrointestinal acute graft versus host disease (aGvHD); its lead product candidate, apraglutide, comprises a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2 (GLP-2) in Phase 3 clinical trials for SBS-IF and Phase 2 trials for additional SBS-IF subtypes and aGvHD; the pipeline also features preclinical small-molecule candidates under the Comet platform, such as VB-1400 for amino acid metabolism disorders and VB-1197 for methylmalonic acidemia. The company, founded in 2019 and headquartered in Basel, Switzerland, operates primarily in Switzerland, Canada and the United States with a focus on rare diseases exhibiting well-defined biology amenable to transformational therapies. In June 2023, VectivBio was acquired by Ironwood Pharmaceuticals Inc in an all-cash transaction valued at approximately $1 billion net of cash and debt, with the merger completed in December 2023, integrating apraglutide's development into Ironwood's GI portfolio while advancing Phase 3 topline results expected by late 2023.
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT
VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT
Why Shares of VectivBio Holding Are Up Today
VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
VECT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of VectivBio Holding AG Is Fair to Shareholders
Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion
Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
VectivBio: Swiss Company With Excellent Data, Upcoming Catalysts
VectivBio to Present at the 2022 Jefferies London Healthcare Conference
VectivBio Announces Date of Extraordinary General Meeting of Shareholders
VectivBio Holding AG (VECT) CEO Luca Santarelli on Q4 2021 Results - Earnings Call Transcript
VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference
6 Underperforming IPO Stocks To Buy On The Dip
VectivBio to Present at the Credit Suisse 30th Annual Healthcare Conference
VectivBio Announces Closing of Comet Therapeutics Acquisition
VectivBio Announces Upcoming Investor Events